Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
May
19
BIMZELX® (bimekizumab-bkzx) demonstrates superior efficacy over SKYRIZI® (risankizumab-rzaa) in psoriatic arthritis: BE BOLD Week 16 data
May
14
UCB Issues Voluntary Recall of Select Lots of CIMZIA® Pre-Filled Syringes (PFS) in the United States
May
04
UCB to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers
Apr
17
UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science
Apr
15
UCB presents new data demonstrating quality-of-life impacts for epilepsy patients and caregivers at AAN 2026 meeting
Apr
13
UCB announces new clinical data from its generalized myasthenia gravis (gMG) portfolio at the 2026 American Academy of Neurology (AAN) meeting
Apr
01
UCB’s Catherine Rives and Alexandria Harrold Recognized by Healthcare Businesswomen’s Association (HBA) as Luminary and Rising Star
Mar
27
Evolving Expectations in Immunologic Disease: Our work with those living with immune-mediated diseases and HCPs
Mar
27
UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis